Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score on Rankin scale · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with prednisolone (moderate certainty).
1 finding from 1 review
Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival (risk of death) ‐ adults with myocarditis, median · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ adults with myocarditis, median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Side effects ‐ mild infusion effects, 12‐month · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes side effects ‐ mild infusion effects, 12‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival (risk of death) ‐ children with myocarditis, 6‐month · children with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ children with myocarditis, 6‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review